Non-alcoholic fatty liver disease-related hepatocellular carcinoma
Open Access
- 31 March 2023
- journal article
- review article
- Published by Korean Liver Cancer Association in Journal of Liver Cancer
- Vol. 23 (1) , 127-142
Abstract
Non-alcoholic fatty liver disease (NAFLD), one of the most common causes of liver disease, is an increasingly common cause of hepatocellular carcinoma (HCC). Several demographic, clinical, and genetic factors contribute to HCC risk in NAFLD patients, which may inform risk stratification scores. Proven efficacious approaches to primary prevention approach in patients with non-viral liver disease remain an area of need. Semi-annual surveillance is associated with improved early tumor detection and reduced HCC-related mortality; however, patients with NAFLD have several challenges to effective surveillance, including under-recognition of at-risk patients, low surveillance utilization in clinical practice, and lower sensitivity of current tools for early-stage HCC detection. Treatment decisions are best made in a multidisciplinary fashion and are informed by several factors including tumor burden, liver dysfunction, performance status, and patient preferences. Although patients with NAFLD often have larger tumor burden and increased comorbidities compared to counterparts, they can achieve similar post-treatment survival with careful patient selection. Therefore, surgical therapies continue to provide a curative treatment option for patients diagnosed at an early stage. Although there has been debate about the efficacy of immune checkpoint inhibitors in patients with NAFLD, current data are insufficient to change treatment selection based on liver disease etiology.Keywords
Funding Information
- National Institutes of Health (NIH R01 CA256977)
This publication has 128 references indexed in Scilit:
- Metformin and reduced risk of hepatocellular carcinoma in diabetic patients: a meta-analysisScandinavian Journal of Gastroenterology, 2012
- Failure Rates in the Hepatocellular Carcinoma Surveillance ProcessCancer Prevention Research, 2012
- Effect of metabolic syndrome on perioperative outcomes after liver surgery: A National Surgical Quality Improvement Program (NSQIP) analysisSurgery, 2012
- Systematic review and meta-analysis of steatosis as a risk factor in major hepatic resectionBritish Journal of Surgery, 2010
- Association of diabetes duration and diabetes treatment with the risk of hepatocellular carcinomaCancer, 2010
- A meta‐analysis of survival rates of untreated patients in randomized clinical trials of hepatocellular carcinoma†Hepatology, 2010
- Pathologic diagnosis of early hepatocellular carcinoma: A report of the international consensus group for hepatocellular neoplasia # †Hepatology, 2009
- Sorafenib in Advanced Hepatocellular CarcinomaNew England Journal of Medicine, 2008
- Randomized controlled trial of screening for hepatocellular carcinomaJournal of Cancer Research and Clinical Oncology, 2004
- Hydrophilicity/ lipophilicity: relevance for the pharmacology and clinical effects of HMG-CoA reductase inhibitorsTrends in Pharmacological Sciences, 1998